Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Sovaldi
Sofosbuvir is a nucleotide analog inhibitor of the hepatitis C virus (HCV) NS5B polymerase, an enzyme essential for viral replication. It is used in combination with other antiviral agents for the treatment of chronic hepatitis C infection. Sofosbuvir is a direct-acting antiviral (DAA) that targets a specific step in the HCV lifecycle. It is generally well-tolerated, though side effects can occur.
For the treatment of chronic hepatitis C virus (HCV) infection in combination with other antiviral agents.
Outcome:
Symptomatic bradycardia
Mechanism:
Amiodarone can enhance sofosbuvir-induced bradycardia.
Outcome:
Increased digoxin levels
Mechanism:
Sofosbuvir can increase digoxin levels.
Outcome:
Slightly reduced sofosbuvir absorption
Mechanism:
Antacids can slightly decrease sofosbuvir absorption.
Most likely new formulation: Pan-genotypic, single-tablet regimens with improved tolerability and shorter treatment durations (2025, 85% confidence).
Based on increasing HCV treatment rates and evolving guidelines, sofosbuvir is expected to maintain a strong market presence in the foreseeable future (90% confidence).
Antiviral, Direct-Acting Antiviral (DAA)
Nucleotide Analog Inhibitor